D-0933-2020 Class II Terminated
FDA drug recall D-0933-2020 was initiated by Fusion IV Pharmaceuticals, Inc. Dba Axia Pharmaceutical on Jan 15, 2020 and is designated Class II. Reason for recall: Lack of Assurance of Sterility The recall status is terminated (terminated Dec 7, 2023).
Recall details
- Product Type
- Drugs
- Report Date
- Mar 11, 2020
- Initiation Date
- Jan 15, 2020
- Termination Date
- Dec 7, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
Product description
Alprostadil/Papaverine Hydrochloride/Phentolamine Mesylate/Atropine Sulfate Injection, 40 mcg/25 mg/0.5mg/0.01mg/ml, For Intracavernosal Use, Freeze, 2.5 mL Multi-dose Vial, Rx only, Axia Pharmaceutical 1990 Westwood Blvd. Ste 135, Los Angeles, CA 90025; NDC 71283-0549-2
Reason for recall
Lack of Assurance of Sterility
Distribution pattern
U.S.A. Nationwide and Puerto Rico, Barbados and Dominican Republic
Code information
Lot #: 12042019+533225, Exp 1/17/2020
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0933-2020
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026